Kbc Group Nv Regenxbio Inc. Transaction History

Kbc Group Nv

$33.1 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$12.89 - $20.82 $13,508 - $21,819	-1,048 Reduced 36.78%	1,801 $32,000
Q3 2023 Feb 15, 2024	SELL	$16.46 - $19.99 $17,250 - $20,949	-1,048 Reduced 36.78%	1,801 $30,000
Q4 2022 Feb 14, 2024	SELL	$20.4 - $24.73 $15,748 - $19,091	-772 Reduced 21.32%	2,849 $65,000
Q3 2022 Feb 15, 2024	BUY	$22.29 - $35.04 $23,359 - $36,721	1,048 Added 58.19%	2,849 $75,000
Q3 2022 Nov 08, 2022	SELL	$22.29 - $35.04 $17,207 - $27,050	-772 Reduced 21.32%	2,849 $75,000
Q1 2022 Feb 14, 2024	BUY	$24.62 - $34.31 $55,887 - $77,883	2,270 Added 168.02%	3,621 $120,000
Q1 2022 May 06, 2022	BUY	$24.62 - $34.31 $55,887 - $77,883	2,270 Added 168.02%	3,621 $120,000
Q4 2021 Feb 14, 2024	SELL	$30.19 - $40.28 $13,585 - $18,126	-450 Reduced 24.99%	1,351 $44,000
Q3 2021 Nov 10, 2021	SELL	$29.09 - $45.68 $10,472 - $16,444	-360 Reduced 21.04%	1,351 $57,000
Q2 2021 Aug 11, 2021	BUY	$32.46 - $40.48 $43,853 - $54,688	1,351 Added 375.28%	1,711 $66,000
Q4 2019 Feb 11, 2020	SELL	$34.54 - $44.87 $345 - $448	-10 Reduced 2.7%	360 $15,000
Q3 2019 Nov 07, 2019	BUY	$31.84 - $50.88 $6,049 - $9,667	190 Added 105.56%	370 $13,000
Q2 2019 Dec 03, 2019	SELL	$42.0 - $59.29 $443,604 - $626,220	-10,562 Reduced 98.32%	180 $9,000
Q2 2019 Jul 30, 2019	BUY	$42.0 - $59.29 $443,604 - $626,220	10,562 Added 5867.78%	10,742 $0
Q1 2019 Dec 03, 2019	SELL	$40.82 - $62.45 $431,140 - $659,596	-10,562 Reduced 98.32%	180 $10,000
Q1 2019 May 10, 2019	BUY	$40.82 - $62.45 $240,919 - $368,579	5,902 Added 121.94%	10,742 $0
Q2 2018 Aug 03, 2018	BUY	$27.2 - $74.35 $131,648 - $359,854	4,840 New	4,840 $0

Others Institutions Holding RGNX

# of Institutions

197

Shares Held

43.2M

Call Options Held

104K

Put Options Held

478K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $413M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account